Notice: Undefined index: tieneTextoCompleto in /var/www/html/bronco/controladores/procedimientos-especificos.php on line 26

Notice: Undefined index: textoCompleto in /var/www/html/bronco/controladores/procedimientos-especificos.php on line 26
Aspectos relevantes en el manejo de la enfermedad pulmonar intersticial difusa | Archivos de Bronconeumología
Archivos de Bronconeumología Archivos de Bronconeumología
Arch Bronconeumol.2009;45 Supl 3:3-8 - Vol. 45 DOI: 10.1016/S0300-2896(09)72851-0
Aspectos relevantes en el manejo de la enfermedad pulmonar intersticial difusa
Key features in the management of diffuse interstitial pulmonary disease
David Iturbe Fernándeza, Ricardo Peris Sánchezb, Alicia Ferreira Morenoc, Estrella Fernández Fabrellasb,,
a Hospital Universitario Marqués de Valdecilla, Santander, España
b Hospital Universitario Dr. Peset, Valencia, España
c Hospital General Universitario Gregorio Marañón, Madrid, España
Resumen

Las enfermedades pulmonares intersticiales difusas (EPID) son un grupo heterogéneo de entidades en las que el denominador común es la afectación de la zona anatómica existente entre la membrana basal del epitelio alveolar y el endotelio capilar, conocido como espacio intersticial. El abordaje diagnóstico, las complicaciones que pueden aparecer en la historia natural de estas enfermedades y sus escasas alternativas terapéuticas hacen de ellas un auténtico reto para el clínico. En esta breve revisión se incidirá en los aspectos más relevantes del manejo de las EPID como son los factores pronósticos, las opciones terapéuticas, incluido el papel del trasplante pulmonar, y el diagnóstico y tratamiento de dos complicaciones de trascendental relevancia en su evolución, como son las exacerbaciones y la hipertensión pulmonar asociada.

Abstract

Diffuse interstitial lung disease is a heterogeneous group of diseases in which the common denominator is involvement of the area between the basement membrane of the alveolar epithelium and the capillary endothelium, known as the interstitial space. Diffuse interstitial lung disease poses a tremendous challenge to the clinician due to the diagnostic approach, the complications that can appear in the natural history of these entities, and the scarcity of available therapeutic resources. This brief review discusses key features of the management of diffuse interstitial pulmonary disease, such as prognostic factors, the therapeutic options –including the role of lung transplantation– and the diagnosis and treatment of two complications with crucial impact on the clinical course of the disease: exacerbations and associated pulmonary hypertension.

Palabras clave
Enfermedad pulmonar intersicial difusa, Exacerbación, Factores pronósticos, Opciones terapéuticas
Keywords
Diffuse interstitial lung disease, Exacerbation, Prognostic factors, Therapeutic options
El Texto completo solo esta disponible en PDF
Bibliografía
1.
American Thoracic Society/European Respiratory Society
International multidisciplinary consensus classification of the idiopathic interstitial pneumonias
Am J Respir Crit Care Med, 165 (2002), pp. 277-304
2.
M. Demetds,A.U. Wells,J.M. Antó,U. Costabel,R. Hubbard,P. Cullinan
Interstitial lung diseases: an epidemiological overview
Eur Respir J, 18 (2001), pp. S2-S16
3.
A. Xaubet,J. Ancochea,R. Blanquer,C. Montero,F. Morell,E. Rodríguez Becerra,Grupo de Investigación en Enfermedades Pulmonares Intersticiales Difusas
Área de Técnicas y Trasplante. SEPAR. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas
Arch Bronconeumol, 39 (2003), pp. 580-600
4.
H.R. Collard,B.B. Moore,K.R. Flaherty,K.K. Brown,R.J. Kaner,T.E. King Jr
Acute exacerbations if idiopathic pulmonary fibrosis
Am J Respir Crit Care Med, 176 (2007), pp. 636-643
5.
J.G. Parambil,J.L. Myers,J.H. Ryu
Diffuse alveolar damage. Uncommon manifestation in patients with connective tissue diseases
Chest, 130 (2006), pp. 553-558
6.
I.N. Park,D.S. Kim,T.S. Shim,C.M. Lim,S.D. Lee,Y. Koh
Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis
Chest, 132 (2007), pp. 214-220
7.
D.S. Kim,H.R. Collard,T.E. King Jr
Classification and natural history of the idiopathic interstitial pneumonias
Proc Am Thorac Soc, 3 (2006), pp. 285-292
8.
J. Behr,J.H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur Respir J, 31 (2008), pp. 1357-1367
9.
J.H. Park,D.S. Kim,I.N. Park,S.J. Jang,M. Kitaichi,A.G. Nicholson
Prognosis of fibrotic interstitial pneumonia
Am J Respir Crit Care Med, 175 (2007), pp. 705-711
10.
A.U. Wells,C.M. Hogaboam
Update un diffuse parenchimal lung disease 2006
Am J Respir Crit Care Med, 175 (2007), pp. 655-660
11.
A.U. Wells,N. Hirani
Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. 63, 2008
Thorax, 63 (2008), pp. V1-V58
12.
J.A. Barberá,P. Escribano,P. Morales,M.A. Gómez,M. Oribe,A. Martínez
Estándares asistenciales en hipertensión pulmonar. Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC)
Arch Bronconeumol, 44 (2008), pp. 87-99
13.
S.B. Venkateshiah,T.D. Yan,T.L. Bonfield,M.J. Thomassen,M. Meziane,C. Czich
An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis
Chest, 130 (2006), pp. 227-237
14.
D.P. Tashkin,R. Elashoff,P.J. Clements,J. Goldin,M.D. Roth,D.E. Furst
Cyclophosphamide versus placebo in scleroderma lung disease
N Engl J Med, 354 (2006), pp. 2655-2666
15.
A.J. Gerbino,C.H. Goss,J.A. Molitor
Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease
Chest, 133 (2008), pp. 455-460
16.
H.R. Collard,J.H. Ryu,W.W. Douglas,M.I. Schwarz,D. Curran-Everett,T.E. King Jr
Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis
Chest, 125 (2004), pp. 2169-2174
17.
M. Demedts,J. Behr,R. Buhl,U. Costabel,R. Dekhuijzen,H.M. Jansen
High-dose acetylcysteine in idiopathic pulmonary fibrosis
N Engl J Med, 353 (2005), pp. 2229-2242
18.
T.J. Williams,J.W. Wilson
Challenges in pulmonary fibrosis: 7-Novel therapies and lung transplantation
Thorax, 63 (2008), pp. 277-284
19.
A. Ferreira,C. Garvey,G.L. Connors,L. Hilling,J. Rigler,S. Farrell
Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response
Chest, 135 (2009), pp. 442-447
20.
J.B. Orens,M. Estenne,S. Arcasoy,J.V. Conte,P. Corris,J.J. Egan
International guidelines for the selection of lung transplant candidates: 2006 update. A consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant, 25 (2006), pp. 745-755
21.
L. Schachna,T.A. Medsger,J.H. Dauber,F.M. Wigley,N.A. Braunstein,B. White
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension
Arthritis Rheum, 54 (2006), pp. 3954-3961
22.
V. Ambrosini,A. Cancellieri,M. Chilosi,M. Zompatori,R. Trisolini,L. Saragoni
Acute exacerbation of idiopathic pulmonary fibrosis: report of a series
Eur Respir J, 22 (2003), pp. 821-826
23.
A. Churg,N.L. Muller,C.I. Silva,J.L. Wright
Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias
Am J Surg Pathol, 31 (2007), pp. 277-284
24.
D.S. Kim,J.H. Park,B.K. Park,J.S. Lee,A.G. Nicholson,T. Colby
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features
Eur Respir J, 27 (2006), pp. 143-150
25.
H. Kubo,K. Nakayama,M. Yanai,T. Suzuki,M. Yamaya,M. Watanabe
Anticoagulant therapy for idiopathic pulmonary fibrosis
Chest, 128 (2005), pp. 1475-1482
26.
S. Nathan,P.W. Noble,M. Tuder
Idiopathic pulmonary fibrosis and pulmonary hypertension. Connecting the dots
Am J Respir Crit Care Med, 175 (2007), pp. 875-880
27.
C.J. Lettieri,S.D. Nathan,D. Barnett,S. Ahmad,A.F. Shorr
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis
Chest, 129 (2006), pp. 746-752
28.
K. Hamada,S. Nagai,S. Tanaka,T. Handa,M. Shigematsu,T. Nagao
Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis
Chest, 131 (2007), pp. 650-656
29.
T. Handa,S. Nagai,S. Miki,Y. Fushimi,K. Ohta,M. Mishima
Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis
Chest, 129 (2006), pp. 1246-1252
30.
S. Trad,Z. Amoura,C. Beiglman,J. Haroche,N. Costedoat,T.H. Boutinle
Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease
Arthritis Rheum, 54 (2006), pp. 184-191
31.
R. Condliffe,D.G. Kiely,A.J. Peacock,P.A. Corris,J.S. Gibbs,F. Vrapi
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era
Am J Respir Crit Care Med, 179 (2009), pp. 151-157
32.
G. Dauriat,H. Mal,G. Thabut,J.F. Mornex,M. Bertocci,F. Trouc
Lung transplantation for pulmonary Langerhans’ cell histiocytosis: a multicenter analysis
Transplantation, 81 (2006), pp. 746-750
33.
D. Polomis,J.R. Runo,K.C. Meyer
Pulmonary hypertension in interstitial lung disease
Curr Opin Pulm Med, 14 (2008), pp. 462-469
34.
Ryu JH, McGoon MD. Pulmonary hypertension associated with interstitial lung disease. 2007, UpToDate.
35.
N. Milman,C.M. Burton,M. Iversen,R. Videbaek,C.V. Jensen,J. Carlsen
Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?
J Heart Lung Transplant, 27 (2008), pp. 329-334
36.
H.R. Collard,K.J. Anstrom,M.I. Schwarz,D.A. Zisman
Sildenafil improves walk distance in idiopathic pulmonary fibrosis
Chest, 131 (2007), pp. 897-899
37.
T.E. King,J. Behr,K. Brown,R.M. Du Bois,L. Lancaster,J.A. De Andrade
BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med, 177 (2008), pp. 75-81
38.
T.P. Fitton,T.R. Kosowski,C.J. Barreiro,V. Chan,N.D. Patel,M.C. Borja
Impact of secondary pulmonary hypertension on lung transplant outcome
J Heart Lung Transplant, 24 (2005), pp. 1254-1259
39.
T.P. Whelan,J.M. Dunitz,R.F. Kelly,L.B. Edwards,C.S. Herrington,M.I. Hertz
Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis
J Heart Lung Transplant, 24 (2005), pp. 1269-1274
Autor para correspondencia.
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
Arch Bronconeumol.2009;45 Supl 3:3-8 - Vol. 45 DOI: 10.1016/S0300-2896(09)72851-0